Mindpax

Mindpax is a digital therapeutics company founded in 2015 by Pavel Nevicky, Daniel Novak, and Jan Ness Novak. The company focuses on the management of severe mental illnesses such as bipolar disorder, schizophrenia, and major depressive disorder. Co-founder Pavel Nevický brings over 20 years of experience in the life sciences and healthcare sectors, having held various positions in the pharmaceutical industry and founded a digital therapeutics company prior to Mindpax. This background in market access strategy, regulatory affairs, and clinical trial design has been instrumental in shaping Mindpax's direction.

The company operates in the health technology market, providing a platform for patients and their healthcare providers, including psychiatrists and psychotherapists. Mindpax's business model centers on its digital solution that facilitates cooperation between patients and their clinical support network. The platform is designed for long-term monitoring to increase patient self-management, prevent relapses, and extend remission periods. In October 2021, Mindpax partnered with EVERSANA to support its commercialization efforts in the United States, targeting the more than 7 million people affected by bipolar disorder in the country.

Mindpax's core offering is a system that combines a mobile application for patients and a web application for clinicians. It tracks both objective and subjective data to provide a comprehensive view of a patient's condition. Objective data is collected passively through commercially available actigraphy sensors that monitor sleep and activity patterns, which are key biomarkers for affective disorders. Subjective data is gathered actively through the mobile app, where patients complete questionnaires, such as the validated ASERT questionnaire, to report on their mood, medication adherence, and significant life events. The system then uses clinically validated algorithms to analyze this data and provide personalized psychoeducational materials and therapeutic interventions directly to the patient. This enables both patients and doctors to make data-driven decisions, understand the individual manifestation of the disorder, and detect early warning signs of potential relapses like depression or manic episodes.

Keywords: digital therapeutics, mental health, bipolar disorder, schizophrenia, remote patient monitoring, health technology, psychoeducation, actigraphy, clinical data analytics, patient engagement, psychiatric disorders, mood tracking, relapse prevention, digital diagnostics, personalized therapy, severe mental illness, healthcare data, mobile health, tele-medical, clinical support